secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001854270-24-000114
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio Q3 net loss $28.9M; cash $10.5M; SENTI-202 data expected Q4 2024
--------------------------------------------------------------------------

- Net loss $28.9M ($6.31 per share); R&D spend $8.7M (down from $9.1M YoY).
- Cash and equivalents $10.5M at Sept 30; subsequent $2.5M CIRM tranche received.
- Phase 1 enrollment of SENTI-202 ongoing; initial safety/efficacy data on track by year-end.
- CIRM grant total $8.0M; $4.9M received through Nov 2024.
- SENTI-301A pilot trial with Celest expects first patient dosing in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000114/0001854270-24-000114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000114/snti-20241114.htm
  HTML page:      https://secwatch.observer/filing/0001854270-24-000114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer